Jubilant Ingrevia Limited (JUBLINGREA) Fair Value & Analysis
Basic Materials · IN · Market cap ₹106B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 4 days ago
Share price −0.8% over the past month.
A solid business, but screening 48% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹484.57). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹213.02 to ₹484.57) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹349.26 – ₹850.29 · fair‑value band ₹213.02 – ₹484.57 · the ₹732.80 price screens above the ₹383.89 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Jubilant Ingrevia Limited (JUBLINGREA) currently trades at ₹732.80, while our model-based Fair Value estimate is ₹383.89, implying the stock looks roughly 47.6% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Jubilant Ingrevia Limited generated revenue of ₹43.9B at a net margin of 6.3%. Revenue grew 12.1% year over year. It earns a return on equity of 9.2%. Net debt stands at ₹6.0B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹213.02 (bear case) to ₹484.57 (bull case); at ₹732.80, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 36% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -68% fair-value upside, at -48%, JUBLINGREA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹592.88) versus Dividend Discount (₹80.89). Highest evidence: Growth DCF (80).
Notify me when JUBLINGREA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 57
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates.
Full company description
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. In addition, it provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. The company serves pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Jubilant Ingrevia Limited reported revenue of ₹43.9B in FY2026 versus ₹49.1B in FY2022, a compound −2.8%/yr. Reported net income was ₹2.8B in FY2026, compounding −12.6%/yr from FY2022.
JUBLINGREA screens 48% overvalued. Compare with Linde plc →
Peer Group
Specialty Chemicals · 672 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $479.43 | $222.03 | -54% |
| Wanhua Chemical Group 600309 | ¥75.06 | ¥68.03 | -9% |
| Novozymes A/S NSISB | kr 416.10 | kr 170.02 | -59% |
| Asian Paints Limited ASIANPAINT | ₹2,756 | ₹664.51 | -76% |
| Solar Industries India Limited SOLARINDS | ₹18,730 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,702 | ₹351.84 | -79% |
| PT Chandra Asri Pacific Tbk TPIA | 2,160 IDR | 2,322 IDR | +8% |
| Berger Paints India Limited BERGEPAINT | ₹559.80 | ₹154.46 | -72% |
| Gujarat Fluorochemicals Limited FLUOROCHEM | ₹4,566 | ₹836.47 | -82% |
| Himadri Speciality Chemical Limited HSCL | ₹778.15 | ₹248.63 | -68% |
Compare Jubilant Ingrevia Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Jubilant Ingrevia Limited (JUBLINGREA) overvalued or undervalued?
What is the fair value of JUBLINGREA?
What is the quality score of JUBLINGREA?
What is the revenue of Jubilant Ingrevia Limited (JUBLINGREA)?
What is the net profit margin of JUBLINGREA?
Does Jubilant Ingrevia Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jubilant Ingrevia Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.